• TRADE NAME: Ubretid (Sanofi)
  • INDICATIONS: Post-operative urinary retention, post operative ileus and intestinal atony, adjunct in the treatment of myasthenia gravis.
  • CLASS: Acetylcholine inhibitor
  • HALF-LIFE: N/A
  • CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
    Beta blockers, Local anesthetics, Muscle relaxants

Please login to view the rest of this drug profile.

Page last updated 07/31/2023

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric